Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vital Living earnings

This article was originally published in The Tan Sheet

Executive Summary

Phoenix-based nutritionals firm recorded a 2,513% increase in sales from continuing operations to $1 mil. with a net loss before discontinued operations of $2.79 mil. in the firm's third quarter (ended Sept. 30), compared with an $11.4 mil. loss the previous year, Vital Living says Nov. 22. The improvement was primarily due to the divestiture of Christopher's Original Formulas herbal supplement business and nutraceuticals firm MAF Bionutritionals; the sales reflect the firm's decision to focus solely on developing and marketing proprietary products, according to CEO Stuart Benson. Vital Living announced the rollout of X-Fat, a diet solution containing a patented form of liquid chitosan, to GNC stores nationwide Nov. 2. The company hopes the product will drive sales over the holiday season...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel